SAIF Partners files proxy materials in connection with Sinovac Biotech meeting

SAIF Partners IV L.P., the largest single investor in Sinovac Biotech (SVA) Ltd., beneficially owning approximately 15% of the outstanding common shares, announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac’s Board of Directors in connection with the special meeting of the shareholders of the company to be held on Tuesday, July 8, 2025 at 8 p.m. Atlantic Standard Time, and at any adjourned, postponed, continued, or rescheduled meeting thereof. Additionally, SAIF Partners issued an open letter to its fellow Sinovac shareholders outlining its “belief that new highly qualified directors are required to effectively resolve the significant challenges Sinovac currently faces and deliver value for all shareholders. In the letter, SAIF details how the Board has not effectively guided Sinovac after the significant chaos of the past several years, including, among other issues, strategic missteps, costly and distracting legal battles, a stock that does not trade, and a large amount of cash that the Company is inexplicably retaining rather than distributing it to shareholders as they should. If elected, SAIF Partners’ nominees will work with management to develop a plan to address these issues and bring disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence to Sinovac. SAIF Partners has outlined the most critical priorities for Sinovac that their nominees would seek to address if elected, including declaring additional dividends, resuming trading of common shares and resolving shareholder disputes.”